Clinical Trials Using Degarelix

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Degarelix. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-8 of 8
  • Ultra-hypofractionated Stereotactic Body Radiation Therapy with or without Short Course Degarelix in Treating Patients with Intermediate-Risk Prostate Cancer

    This randomized phase III trial studies how well ultra-hypofractionated stereotactic body radiation therapy alone works compared to ultra-hypofractionated stereotactic body radiation therapy and short course degarelix in treating patients with intermediate-risk prostate cancer. Ultra-hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using degarelix may fight prostate cancer by lowering the amount of testosterone the body makes. Giving ultra-hypofractionated stereotactic body radiation therapy and a short course of degarelix may work better in treating patients with prostate cancer.
    Location: 6 locations

  • A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

    This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
    Location: 7 locations

  • Docetaxel and Degarelix in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer

    This phase II trial studies how well docetaxel and degarelix work in treating patients with newly diagnosed prostate cancer that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of tumor cells. Hormone therapy using degarelix may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells. Giving docetaxel and degarelix may work better in treating patients with prostate cancer.
    Location: 2 locations

  • Androgen Deprivation Therapy, Docetaxel, External Beam Radiation Therapy, and Stereotactic Body Radiation Therapy in Treating Patients with Prostate Cancer

    This phase II trial studies the side effects of androgen deprivation therapy, docetaxel, external beam radiation therapy, and stereotactic body radiation therapy work in treating patients with prostate cancer. Androgen deprivation therapy, such as leuprolide acetate, triptorelin, degarelix, and bicalutamide may lessen the amount of androgen made by the body. Drugs used in the chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving androgen deprivation therapy, docetaxel, external beam radiation therapy, and stereotactic body radiation therapy may work better in treating patients with prostate cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men with Localized Prostate Cancer Pre-prostatectomy

    This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and / or blocking the use of androgen by the tumor cells.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • High-Dose Brachytherapy in Treating Patients with Prostate Cancer

    This phase I / II trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor and may be a better treatment in patients with prostate cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer

    This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.
    Location: 2 locations

  • Effects of Endocrine Therapy with or without Trametinib or Dasatinib in Patients with Localized, Untreated Prostate Cancer Undergoing Surgery

    This phase II trial studies the effects of endocrine (hormone) therapy when given with or without treatment that targets cancer cells (trametinib or dasatinib) in patients with untreated prostate cancer that has not spread to other parts of the body, and who are undergoing surgery to remove the prostate. Hormones, such as androgen, may cause cancer. Hormone therapies may fight prostate cancer by lowering the amount of androgen the body makes. However, some cancers eventually become resistant to hormone therapy and continue to grow. Studying tissue samples from patients with prostate cancer may help researchers understand how prostate cancer becomes resistant to hormone therapy, and whether adding treatment that targets cancer cells may help prevent resistance to hormone therapy.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California